Taro Pharma Cash Flow - Annual (NYSE:TARO)

Add to My Stocks
$98.73 $0.77 (0.77%) TARO stock closing price Sep 18, 2018 (Closing)

The Taro Pharma cash flow statement is one of the important reports considered by investors doing a fundamental analysis of the company. The profit-loss statement shows Taro Pharma profits, the balance sheet shows Taro Pharma debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Items like capital purchases, bank loan payments etc. which have a direct impact on the cash position of a company come out through the statemement of cash flows and help an investor who undertakes the Taro Pharma stock analysis. Taro Pharma generated $323.68M cash from operating activities in 2018. The cash from operating activities for Taro Pharma is $ 2018, which saw a decrease from previous year.

View details of Taro Pharma cash flows for latest & last 10 financial years
show more
Quarterly
Annual
View Previous Years
View Next Years
Fiscal year is Apr - Mar201820172016201520142013201220112010
Net Income Cash Flow
210.07M456.66M541.27M484.83M360.85M266.87M47.4M25.95M10.24M
Depreciation Depletion Amortization Cash-Flow16.49M14.82M14.84M15.79M16.56M17.76M4.59M4.7M4.58M
Net Increase (Decrease) in Assets Liabilities7.66M-80.08M-137.16M-60.06M-36.95M27.35M-5.95M-1.62M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net89.45M46.12M-23.82M-93.84M-79.84M--1.26M-0.34M2.64M
Net Cash from (used by) Operating Activities
323.68M437.53M395.12M406.78M357.64M248.65M78.09M24.35M15.84M
Increase (Decrease) in Prop Plant And Equipment-25.81M-27.24M-18.97M-19.99M-21.24M-9.46M-1.58M-0.88M-0.51M
Acquisition Disposition of Subsidiaires---------
Increase (Decrease) in Investments-213.17M-90.47M-300.62M-43.34M-0.1M-241.91M-4.9M--11.15M
Other Cash Inflow (Outflow) from Investment Activities-2.65M-0.05M34.86M-28.74M-151.95M7.44M22.07M-10.1M-0.02M
Net Cash from (used by) Investment Activities
-241.63M-117.77M-284.73M-92.08M-173.29M-243.93M15.58M-10.99M-11.69M
Issuance (Purchase) of Equity Shares-106.98M-294.89M-9.45M--191.58M6.58M-8.55M-
Issuance (Repayment) of Debt Securities---5.88M--11.87M-10.74M-6.59M--1.42M
Increase (Decrease) in Bank & Other Borrowings----10.94M---2.42M3.71M
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities---------
Net Cash from (used by) Financing Activities
-106.98M-294.89M-15.33M-10.91M-203.46M-3.32M-6.58M10.99M2.28M
Effect of Exchange Rate Changes on Cash1.14M-1.21M--32.11M-8.2M-2.37M1.17M--0.09M
Net Change in Cash & Cash Equivalents
-23.78M23.64M95.11M271.67M-27.31M-0.98M88.26M24.72M6.34M
Cash & Equivalents at Beginning of Year600.39M576.75M481.64M209.96M237.28M238.26M150M54.14M98.43M
Cash & Equivalents at Year End576.61M600.39M576.75M481.64M209.96M237.28M238.26M78.87M104.78M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Taro Pharma stock price history and Taro Pharma stock comparison chart inevitably reflect its cash flow situation.

  • Taro Pharma had a Net Change in Cash and Cash Equivalents of $-23.78M for the latest year 2018. If a firm is able to grow its cash, it is considered to be a positive signal and could lead to a jump in the Taro Pharma stock price, albeit too much cash on hand can imply the company has no or limited avenues for growth in which to invest this cash.
  • Cash Flow from operating activities: This is the cash that the company receives from ongoing operations. Taro Pharma gained $323.68M cash from operations. It is important to check this to see where the company is getting its money from.
  • Cash Flow from investment activities: This includes buying/selling of land and equipment, acquisitions and mergers, sell-off, investment in other companies like buying bonds, stocks etc., and was $-241.63M for TARO in last 2018 report.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $-106.98M for Taro Pharma. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.

Key Financial Ratios For Taro Pharma Cash Flow

FCF margin
0.95

Annual Cash Flow Statements For Taro Pharmaceutical Industries Ltd. Peers

Anacor Pharma cash flow, Bayer AG cash flow, BAUSCH HEALTH cash flow, HYPERA SA cash flow, Pfizer cash flow